Physician profile
John K John
NPI 1033105739
$17,124.96
in general payments reported to CMS, 2019-2025
55 companies · $2,326 in 2025
The $2,326 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,563 · 2020: $2,121 · 2021: $1,642 · 2022: $2,557 · 2023: $3,168 · 2024: $2,749 · 2025: $2,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,242.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,218.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,893.00 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,871.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,434.10 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,336.32 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $968.47 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $903.48 | 2019-2025 | |
| Pfizer INC. | $706.68 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $498.27 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $447.52 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $386.94 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $339.22 | 2020-2025 | Verquvo, Gardasil 9, Capvaxive |
| Amarin Pharma, INC. | $338.36 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $335.85 | 2019-2025 | Xifaxan, Trulance |
| Astellas Pharma US INC | $206.77 | 2019-2025 | Veozah |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.